Editas Medicine Announces Transition of Chief Medical Officer

CAMBRIDGE, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Medical Officer, Gerald Cox, M.D., Ph.D., will be stepping down from the Company at the end of the year. A search is underway to find a successor to Dr. Cox, and the Company continues to execute on its near-term and long-term goals of advancing transformative genomic medicines.

“On behalf of the entire Editas team, I sincerely thank Gerry for his many contributions in helping translate the science of CRISPR into medicines,” said Katrine Bosley, President and Chief Executive Officer, Editas Medicine. “Gerry has been instrumental in shaping our clinical strategy, establishing our clinical operations, and advancing our LCA10 program to the cusp of the clinic. We look forward to working with him on a smooth transition through the end of the year and wish him well in his next endeavor.”

“I have greatly enjoyed the privilege of working alongside a tremendous and talented team here at Editas Medicine, and together we have advanced the LCA10 program and other important genome editing programs,” said Dr. Cox. “With this progress and the company’s overall evolution, the end of 2018 felt like a natural transition point. I look forward to working closely with the team on the submission of our IND for our LCA10 program and to seeing Editas Medicine’s continued success long-term.”

About Editas Medicine

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit . 

Forward-Looking Statements

This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words “aim,” ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’  ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  Forward-looking statements in this press release include statements regarding the Company’s goal of advancing transformative genomic medicines and submitting an Investigational New Drug application for its LCA10 program. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.  Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements.  These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future.  Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Media

Cristi Barnett

(617) 401-0113

Investors

Mark Mullikin

(617) 401-9083